NCT05296135 (PREDAPT-HNSCC2) is a clinical trial of OncoPrism-HNSCC™ in Head and Neck Squamous Cell Carcinoma, sponsored by Cofactor Genomics, Inc..

Who is sponsoring NCT05296135?

NCT05296135 is sponsored by Cofactor Genomics, Inc..

What drugs are being tested in NCT05296135?

Interventions in NCT05296135: OncoPrism-HNSCC™.

What condition does NCT05296135 study?

NCT05296135 studies Head and Neck Squamous Cell Carcinoma.

Is NCT05296135 still recruiting?

NCT05296135 is currently withdrawn. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT05296135: PREDAPT-HNSCC2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer

Withdrawn Last updated 27 February 2026

What this trial tests

trial testing OncoPrism-HNSCC™ in Head and Neck Squamous Cell Carcinoma. Withdrawn.

Timeline

5 February 2020

Primary endpoint
20 February 2025

20 February 2025

Quick facts

Lead sponsor	Cofactor Genomics, Inc.
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	5 February 2020
Primary completion	20 February 2025
Estimated completion	20 February 2025
Sites	1 location across United States

Drugs / interventions tested

OncoPrism-HNSCC™

Conditions studied

Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →

Sponsor

Cofactor Genomics, Inc.

Who can join

18 and older, any sex, with Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate the clinical validity and clinical utility of the OncoPrism-HNSCC (Head and Neck Squamous Cell Carcinoma) test.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05296135 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cofactor Genomics, Inc.
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05296135.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing